de Novo Lesions in Native Coronary Arteries clinical trials at UCSF
1 research study open to eligible people
De novo lesions in native coronary arteries are new narrow spots in the heart's own blood vessels. UCSF is testing a device that uses a medicine-coated balloon versus usual stent procedures to treat these narrowings. UCSF is tracking safety and how well blood flow is restored.
AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions
open to eligible people ages 18 years and up
AGENT DCB STANCE is a prospective, multicenter, open-label, 1:1 randomized controlled study designed to assess the safety and effectiveness of a treatment strategy with the AGENT Drug-Coated Balloon compared to standard of care percutaneous coronary intervention (PCI) treatment with drug eluting stent (DES) and/or balloon angioplasty in patients with de novo coronary lesions. Subjects must have a de novo target lesion located in a native coronary artery.
San Francisco, California and other locations
Our lead scientists for de Novo Lesions in Native Coronary Arteries research studies include Yousif Ahmad, MD.
Last updated: